Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827462 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL1985823 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2175496 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2176899 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2177991 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2174526 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL132521 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2173439 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL443449 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL294141 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2946795-B1 | TISSUE ADHESIVE AND PROCESS FOR PRODUCING SAME | NAT INST MATERIALS SCIENCE (JP) | 2019-04-17 | — | — | EP | claimed |
| US-10064973-B2 | Tissue adhesive and method for producing same | NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) | 2018-09-04 | — | — | US | claimed |
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| US-20150359924-A1 | TISSUE ADHESIVE AND METHOD FOR PRODUCING SAME | NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) | 2015-12-17 | — | — | US | claimed |
| EP-2946795-A1 | TISSUE ADHESIVE AND PROCESS FOR PRODUCING SAME | National Institute for Materials Science (JP) | 2015-11-25 | — | — | EP | claimed |
| US-6110933-A | AN ENZYME INHIBITOR TREATING PANCREATITIS, HEPATITIS, CHRONIC RENAL FAILURE, ENDOTOXIN SHOCK, GRAM-NEGATIVE SEPTIC SHOCK, ARTHRITIS, RESPIRATORY DISEASE, HEART DISEASE, ALLERGIC DISEASE, THROMBOSIS, ARTERIOSCLEROSIS, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-29 | — | — | US | claimed |
| US-5352689-A | Rhizoxin derivatives and their use as anti-tumor agents | SANKYO COMPANY, LIMITED (JP) | 1994-10-04 | — | — | US | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024101446-A1 | MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME | ルクサナバイオテク株式会社 | 2024-05-16 | — | — | WO | disclosed |
| CN-112513062-B | Oligonucleotide-containing small cell lung cancer therapeutic agent | 国立大学法人大阪大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | OSAKA UNIVERSITY (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117964674-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964673-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| CN-1052481-A | Lipoid category-A with immunocompetence and anti-tumor activity is like thing | SANKYO CO (JP) | 1991-06-26 | — | — | CN | disclosed |
| CN-1040982-A | Nitragin (rhizoxin) derivative and as antineoplastic agent | SANKYO CO (JP) | 1990-04-04 | — | — | CN | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4891363-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY LIMITED (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0251827-A2 | New cyclic ether derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | UPF1, RBM17, NSUN2 | LMNA 385/4885KDM4C 3149/4885TRPV1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.